MedTrace Logo

Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy

NCT01379196 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2017-04-27

No results posted yet for this study

Summary

The purpose of this study is to examine the effects of Azithromycin (a macrolide class antibiotic), given three times weekly, for patients with active moderate-severe, non sight-threatening, Graves Orbitopathy.

Indices for follow-up will include:

* Clinical activity score
* Anti-TSH receptor antibody levels
* Thickening of extraocular muscles per ultrasound
* Quality of life score for Graves Orbitopathy patients

Conditions

  • Graves Ophthalmopathy

Interventions

DRUG

Azithromycin

Tab. Azithromycin 500 mg PO three times weekly for 3 months

Sponsors & Collaborators

  • Rabin Medical Center

    lead OTHER

Principal Investigators

  • Hadas Kalish, MD · Neuro-Ophthalmology Unit, Rabin Medical Center, Petah Tikva 49100 Israel

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2014-11-30
Completion
2014-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01379196 on ClinicalTrials.gov